Genetic Circuits in Salmonella typhimurium
Synthetic biology has rapidly progressed over the past decade and is now positioned to impact important problems in health and energy. In the clinical arena, the field has thus far focused primarily on the use of bacteria and bacteriophages to overexpress therapeutic gene products. The next gene...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
American Chemical Society (ACS)
2012
|
| Online Access: | http://hdl.handle.net/1721.1/75313 https://orcid.org/0000-0002-1293-2097 https://orcid.org/0000-0001-7302-4394 |
| _version_ | 1811095785402531840 |
|---|---|
| author | Prindle, Arthur Selimkhanov, Jangir Danino, Tal Samayoa, Phillip Goldber, Anna Hasty, Jeff Bhatia, Sangeeta N |
| author2 | Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
| author_facet | Massachusetts Institute of Technology. Institute for Medical Engineering & Science Prindle, Arthur Selimkhanov, Jangir Danino, Tal Samayoa, Phillip Goldber, Anna Hasty, Jeff Bhatia, Sangeeta N |
| author_sort | Prindle, Arthur |
| collection | MIT |
| description | Synthetic biology has rapidly progressed over the
past decade and is now positioned to impact important problems
in health and energy. In the clinical arena, the field has thus far
focused primarily on the use of bacteria and bacteriophages to
overexpress therapeutic gene products. The next generation of
multigene circuits will control the triggering, amplitude, and
duration of therapeutic activity in vivo. This will require a host
organism that is easy to genetically modify, leverages existing
successful circuit designs, and has the potential for use in humans.
Here, we show that gene circuits that were originally constructed
and tested in Escherichia coli translate to Salmonella typhimurium, a
therapeutically relevant microbe with attenuated strains that have
exhibited safety in several human clinical trials. These strains are essentially nonvirulent, easy to genetically program, and
specifically grow in tumor environments. Developing gene circuits on this platform could enhance our ability to bring
sophisticated genetic programming to cancer therapy, setting the stage for a new generation of synthetic biology in clinically
relevant microbes. |
| first_indexed | 2024-09-23T16:27:53Z |
| format | Article |
| id | mit-1721.1/75313 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T16:27:53Z |
| publishDate | 2012 |
| publisher | American Chemical Society (ACS) |
| record_format | dspace |
| spelling | mit-1721.1/753132022-09-29T19:53:46Z Genetic Circuits in Salmonella typhimurium Prindle, Arthur Selimkhanov, Jangir Danino, Tal Samayoa, Phillip Goldber, Anna Hasty, Jeff Bhatia, Sangeeta N Massachusetts Institute of Technology. Institute for Medical Engineering & Science Harvard University--MIT Division of Health Sciences and Technology Danino, Tal Bhatia, Sangeeta N. Synthetic biology has rapidly progressed over the past decade and is now positioned to impact important problems in health and energy. In the clinical arena, the field has thus far focused primarily on the use of bacteria and bacteriophages to overexpress therapeutic gene products. The next generation of multigene circuits will control the triggering, amplitude, and duration of therapeutic activity in vivo. This will require a host organism that is easy to genetically modify, leverages existing successful circuit designs, and has the potential for use in humans. Here, we show that gene circuits that were originally constructed and tested in Escherichia coli translate to Salmonella typhimurium, a therapeutically relevant microbe with attenuated strains that have exhibited safety in several human clinical trials. These strains are essentially nonvirulent, easy to genetically program, and specifically grow in tumor environments. Developing gene circuits on this platform could enhance our ability to bring sophisticated genetic programming to cancer therapy, setting the stage for a new generation of synthetic biology in clinically relevant microbes. National Institutes of Health (U.S.) (Grant GM069811) Misrock Foundation (Postdoctoral Fellowship) 2012-12-10T15:22:00Z 2012-12-10T15:22:00Z 2012-08 2012-07 Article http://purl.org/eprint/type/JournalArticle 2161-5063 http://hdl.handle.net/1721.1/75313 Prindle, Arthur et al. “Genetic Circuits in Salmonella Typhimurium.” ACS Synthetic Biology 1.10 (2012): 458–464. Copyright © 2012 American Chemical Society https://orcid.org/0000-0002-1293-2097 https://orcid.org/0000-0001-7302-4394 en_US http://dx.doi.org/10.1021/sb300060e ACS Synthetic Biology Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf American Chemical Society (ACS) American Chemical Society |
| spellingShingle | Prindle, Arthur Selimkhanov, Jangir Danino, Tal Samayoa, Phillip Goldber, Anna Hasty, Jeff Bhatia, Sangeeta N Genetic Circuits in Salmonella typhimurium |
| title | Genetic Circuits in Salmonella typhimurium |
| title_full | Genetic Circuits in Salmonella typhimurium |
| title_fullStr | Genetic Circuits in Salmonella typhimurium |
| title_full_unstemmed | Genetic Circuits in Salmonella typhimurium |
| title_short | Genetic Circuits in Salmonella typhimurium |
| title_sort | genetic circuits in salmonella typhimurium |
| url | http://hdl.handle.net/1721.1/75313 https://orcid.org/0000-0002-1293-2097 https://orcid.org/0000-0001-7302-4394 |
| work_keys_str_mv | AT prindlearthur geneticcircuitsinsalmonellatyphimurium AT selimkhanovjangir geneticcircuitsinsalmonellatyphimurium AT daninotal geneticcircuitsinsalmonellatyphimurium AT samayoaphillip geneticcircuitsinsalmonellatyphimurium AT goldberanna geneticcircuitsinsalmonellatyphimurium AT hastyjeff geneticcircuitsinsalmonellatyphimurium AT bhatiasangeetan geneticcircuitsinsalmonellatyphimurium |